Patents by Inventor Dezider Grunberger

Dezider Grunberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of cataracts and other disorders
    Patent number: 6313165
    Abstract: A method of inhibiting the formation of a cataract in an eye by contacting the eye with a compound having the structure: is described. Also described is a method of inhibiting the progression of cataract formation in an eye. Methods comprising administering a pharmaceutical composition comprising the above compound to inhibit the formation of a cataract in the eye of a subject and to inhibit progression of cataract formation in the eye of a subject are also described. The above compound also prevents diseases resulting from oxidative stress, including diseases comprising tumor formation resulting from oxidative stress, and also inhibits the progression of diseases resulting from oxidative stress. The above compound may furthermore be used to treat an HIV infection when combined in a pharmaceutical composition with a substance which inhibits HIV replication.
    Type: Grant
    Filed: December 23, 1996
    Date of Patent: November 6, 2001
    Assignees: The Trustees of Columbia University in the City of New York, New York University
    Inventors: Dezider Grunberger, Krystyna Frenkel
  • Inhibition of nuclear transcription factor NF-.kappa.B by caffeic acid phenethyl ester (CAPE), derivatives of CAPE, capsaicin (8-methyl-N-vanillyl-6-nonenamide) and resiniferatoxin
    Patent number: 5981583
    Abstract: The present invention is drawn to the inhibition of activation of NF-.kappa.B by caffeic acid phenethyl ester (CAPE) and two analogues of CAPE. Tumor necrosis factor (TNF) activation of NF-.kappa.B is completely blocked by CAPE in a dose- and time-dependent manner, as is activation by phorbol ester, ceramide, hydrogen peroxide, and okadaic acid. Additionally, capsaicin (8-methyl-N-vanillyl-6-noneamide) and resiniferatoxin inhibit the activation of NF-.kappa.B induced by different agents.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: November 9, 1999
    Assignee: Research Development Foundation
    Inventors: Bharat B. Aggarwal, Dezider Grunberger
  • Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
    Patent number: 5591773
    Abstract: A method of inhibiting the formation of a cataract in an eye by contacting the eye with a compound having the structure: ##STR1## is described. Also described is a method of inhibiting the progression of cataract formation in an eye. Methods comprising administering a pharmaceutical composition comprising the above compound to inhibit the formation of a cataract in the eye of a subject and to inhibit progression of cataract formation in the eye of a subject are also described. The above compound also prevents diseases resulting from oxidative stress, including diseases comprising tumor formation resulting from oxidative stress, and also inhibits the progression of diseases resulting from oxidative stress. The above compound may furthermore be used to treat an HIV infection when combined in a pharmaceutical composition with a substance which inhibits HIV replication.
    Type: Grant
    Filed: March 14, 1994
    Date of Patent: January 7, 1997
    Assignees: The Trustees of Columbia University in the City of New York, New York University
    Inventors: Dezider Grunberger, Krystyna Frenkel
  • Caffeic acid esters and methods of producing and using same
    Patent number: 5008441
    Abstract: The invention relates to a compound having the structure: ##STR1##wherein R comprises a phenethyl, butyl, hexyl or ethyl group.The invention also related to methods of isolating and producing the compound, methods of treating inflammation in a subject and methods of substantially inhibiting the growth of transformed cells in a population of normal and transformed cells.
    Type: Grant
    Filed: June 20, 1989
    Date of Patent: April 16, 1991
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Koji Nakanishi, Eugene M. Oltz, Dezider Grunberger